Wescott Financial Advisory Group LLC acquired a new stake in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,486 shares of the specialty pharmaceutical company’s stock, valued at approximately $29,000.
Other large investors also recently bought and sold shares of the company. Millennium Management LLC increased its holdings in Ampio Pharmaceuticals by 600.1% during the 1st quarter. Millennium Management LLC now owns 1,910,256 shares of the specialty pharmaceutical company’s stock worth $3,228,000 after purchasing an additional 1,637,386 shares during the period. SRS Capital Advisors Inc. purchased a new position in Ampio Pharmaceuticals during the 2nd quarter worth $1,051,000. HRT Financial LP acquired a new stake in Ampio Pharmaceuticals during the 1st quarter worth about $839,000. BlackRock Inc. lifted its position in Ampio Pharmaceuticals by 14.5% during the 1st quarter. BlackRock Inc. now owns 3,554,149 shares of the specialty pharmaceutical company’s stock worth $6,007,000 after acquiring an additional 449,922 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Ampio Pharmaceuticals by 2,517.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 320,964 shares of the specialty pharmaceutical company’s stock worth $542,000 after acquiring an additional 308,700 shares during the period. 22.53% of the stock is owned by institutional investors and hedge funds.
Shares of Ampio Pharmaceuticals stock traded up $0.22 on Wednesday, hitting $1.66. The company’s stock had a trading volume of 319,248 shares, compared to its average volume of 2,406,000. Ampio Pharmaceuticals, Inc. has a 1 year low of $0.72 and a 1 year high of $2.98. The firm’s fifty day moving average is $1.48. The firm has a market cap of $332.76 million, a P/E ratio of -22.25 and a beta of 1.77.
Separately, Zacks Investment Research cut Ampio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, July 5th.
In other Ampio Pharmaceuticals news, CFO Dan Stokely sold 22,500 shares of the business’s stock in a transaction that occurred on Friday, June 25th. The stock was sold at an average price of $1.79, for a total transaction of $40,275.00. Following the completion of the sale, the chief financial officer now directly owns 50,815 shares in the company, valued at approximately $90,958.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. 3.59% of the stock is currently owned by insiders.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.
Further Reading: QQQ ETF
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.